A planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep (belantamab mafodotin) as a second-line treatment for relapsed or refractory multiple myeloma produced positive headline results.
The EU has approved Sarclisa (isatuximab-irfc) in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma ineligible for autologous stem cell transplant, based on data from the IMROZ phase III study.
